UNSPSC 51262414: Terbutaline sulfate

This classification denotes a bronchodilator and beta-adrenergic agonist with the molecular formula 2C12H19NO3.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 576PU70Y8E, chemically known as 1,3-benzenediol, 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)- (9ci) but more generally known as terbutaline sulfate, which bears US NIH Compound Identifier 5403. European Medicines Agency schedules Terbutaline sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04724MIG.

UNSPSC 51262414 Terbutaline sulfate is a Commodity code nominally identifying a specific bronchodilator pharmaceutical product, but recent state and local solicitations tagged under this code show minimal activity directly matching the substance itself. The one opportunity explicitly posted under the code—Seminole County, Florida's IFB60459723LAS for Naloxone and Safe Drug Deactivation Systems—targets opioid-overdose reversal agents and harm-reduction equipment rather than terbutaline or respiratory medications. A second opportunity from the Texas Health and Human Services Commission (HHS0017013) appears to be an RFI exploring direct-to-manufacturer pharmacy contracting models and does not reference terbutaline or any specific pharmaceutical product. State and local procurement activity under this code does not align with purchasing respiratory or bronchodilator medications at scale; the mismatch suggests either tagging error or discontinuous demand for the specific active ingredient across state and local jurisdictions.

Seminole County, Florida posted the only substantive opportunity in the recent block, issuing an IFB on June 30, 2026 with a response deadline of July 26, 2023 (note: date mismatch in source), seeking annual procurement of naloxone units and deactivation systems with quarterly deliveries to the county community health building, fixed-fee pricing, and a two-year initial term with a one-year renewal option. The Texas HHS RFI (posted April 3, 2026) is exploratory in nature and does not constitute a formal competitive solicitation. No set-aside designations or budget ranges appear in either opportunity. The code shows limited recent decision-relevant activity for vendors pursuing terbutaline or related respiratory pharmaceutical supplies under standard state and local procurement channels.